Alexandria Real Estate Eq Inc Stock Price, News & Analysis

On November 16, 2021, Alexandria Real Estate Equities (NYSE: ARE) announced plans to enhance R&D and next-gen manufacturing in Research Triangle, N.C. The company is partnering with biotechnology firms and acquiring development sites to help these companies control their medicine quality and supply chains. Alexandria's recent acquisition includes 95 acres for biomanufacturing centers. They aim to foster integrated manufacturing capabilities, crucial for developing complex medicines. Alexandria's market cap stands at $38.6 billion, with a significant presence in major innovation hubs across North America.

On October 25, 2021, Alexandria Real Estate Equities (NYSE:ARE) announced its financial results for Q3 2021, showing total revenues of $547.8 million, a 0.5% increase from Q3 2020. Net income attributable to common stockholders rose to $101.3 million ($0.67 per share), reflecting strong demand for office and laboratory spaces. The company secured a 15-year lease with Moderna for a new HQ, marking its largest life science lease. Year-to-date leasing volume reached 5.4 million RSF, with a 39.4% rental rate increase. S&P upgraded its credit outlook to BBB+/Positive, emphasizing strong fundamentals.

On October 18, 2021, Alexandria Venture Investments, a part of Alexandria Real Estate Equities (NYSE: ARE), was named the most active biopharma corporate investor by new deal volume for the fourth consecutive year. The recognition is part of Silicon Valley Bank's Healthcare Investments and Exits: Mid-Year 2021 Report. Alexandria also ranked as the top new Series A investor in biopharma. The firm has a market capitalization of $36.3 billion and has invested in notable companies such as GRAIL and Thrive Earlier Detection, enhancing its role in advancing health science.

On September 30, 2021, Alexandria Real Estate Equities (NYSE: ARE) announced its collaboration with Moderna to develop a new 462,000 RSF headquarters and R&D facility at 325 Binney Street, Cambridge. This cutting-edge building, designed to be the most sustainable laboratory in Cambridge, aims for net-zero energy consumption and various environmental certifications. Construction is underway, with completion expected in 2023, supporting Moderna's growth in mRNA medicines. Alexandria has expanded its asset base to approximately 15 million square feet in Greater Boston, emphasizing its role in the life science ecosystem.

Moderna, Inc. (NASDAQ: MRNA) has announced plans to invest in a new 462,000 sq. ft. science center in Cambridge, Massachusetts, aiming for LEED Zero certification. This facility will support its mRNA therapeutics and vaccines, focusing on sustainability and collaboration. Construction has begun, with phased move-in expected in 2023. Alexandria Real Estate Equities (NYSE: ARE) is the development partner, while Jones Lang LaSalle (NYSE: JLL) facilitated the site selection. Moderna's pipeline includes 37 programs, 22 of which are in clinical studies.

Alexandria Real Estate Equities (NYSE: ARE) announced that OneFifteen, a non-profit healthcare ecosystem for opioid addiction recovery, received an honorable mention in Fast Company's 2021 Innovation by Design Awards. This award highlights Alexandria's role in tackling the opioid crisis, which caused over 95,000 deaths in the U.S. by February 2021. The OneFifteen campus in Dayton, Ohio, developed in partnership with Verily, features comprehensive addiction care and has helped over 3,500 patients since 2019. This recognition emphasizes Alexandria's commitment to innovative solutions in public health.